Platelet inhibitors and bleeding in cardiac surgical patients.

Published

Other Article

A variety of measures may affect bleeding and transfusion requirements in abciximab-treated patients. These measures include recognition of the risk factors for increased bleeding and transfusion requirements, use of proper transfusion practices, conservation or increasing of red cell mass, appropriate heparin dosing and protamine reversal, reversal of anticoagulation, awareness of factors that affect activated clotting time (ACT), and appropriate anticoagulation for cardiopulmonary bypass.

Full Text

Duke Authors

Cited Authors

  • Levy, JH

Published Date

  • August 2000

Published In

Volume / Issue

  • 70 / 2 Suppl

Start / End Page

  • S9 - 11

PubMed ID

  • 10966005

Pubmed Central ID

  • 10966005

International Standard Serial Number (ISSN)

  • 0003-4975

Digital Object Identifier (DOI)

  • 10.1016/s0003-4975(00)01603-9

Language

  • eng

Conference Location

  • Netherlands